Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

Vor Biopharma Inc. (NYSE:VOR) was the target of unusually large options trading on Thursday. Traders acquired 13,899 call options on the company. This is an increase of approximately 11,779% compared to the typical daily volume of 117 call options.

Vor Biopharma Stock Performance

Shares of NYSE VOR opened at $0.89 on Friday. The stock’s 50-day simple moving average is $0.35 and its 200-day simple moving average is $0.83. The firm has a market capitalization of $111.21 million, a PE ratio of -0.54 and a beta of -0.51. Vor Biopharma has a fifty-two week low of $0.13 and a fifty-two week high of $1.80.

Analyst Ratings Changes

VOR has been the subject of several analyst reports. Citizens Jmp cut Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 9th. Oppenheimer reiterated an “outperform” rating and issued a $8.00 price objective on shares of Vor Biopharma in a research note on Friday, March 21st. JMP Securities restated a “market perform” rating and set a $6.00 target price on shares of Vor Biopharma in a research note on Friday, May 9th. Baird R W cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Finally, Jones Trading cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $7.06.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds have recently added to or reduced their stakes in VOR. Two Sigma Investments LP boosted its holdings in shares of Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after buying an additional 25,930 shares in the last quarter. Money Concepts Capital Corp lifted its position in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after acquiring an additional 26,535 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in Vor Biopharma in the fourth quarter valued at $33,000. Northern Trust Corp boosted its stake in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after acquiring an additional 44,252 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Vor Biopharma during the fourth quarter worth about $60,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.